Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB
NCT02004600 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2015-09-30
Summary
The hereditary dystrophic epidermolysis bullosa are genodermatosis responsible of a poor adhesion of the epidermis to the dermis pulling a large mucocutaneous fragility and recurrent spontaneous or posttraumatic bullous detachment. They are caused by mutations in the COL7A1 gene encoding for the collagen VII.
No curative treatment is avaible. The main cause of patients death is the development of squamous cell carcinoma, sometimes multiple and paticularly aggressive in repeated healing part. The photodynamic therapy (PDT) is one of technical reference of multiple actinic keratoses lesions for adults, which are also pre-epithelioma lesions. The PDT is well tolerated even by the elderly and requires only a single session.
The main objective of this study is to determine the efficiency of the photodynamic therapy in the treatment of epidermic dysplasies for patients affected by dystrophic epidermolysis bullosa (DEB). The secondary objectives are to evaluate the tolerance of this treatment in terms of pain and healing, and to evaluate the contribution of confocal microscopy in the diagnosis of epidermal dysplasia for patients affected by hereditary dystrophic epidermolysis bullosa. The main evaluation criterion is the cutaneous biopsy before and after (M2) a PDT session of an epidermal dysplasia area. The secondary criteria are the evaluation of the pain during the PDT session and the healing of the cutaneous lesion at M0, M2 and M4 (lesion area and healing time) and correlation histology / MC. Each patient with a suspicious lesion will be biopsied. In case of agreement for this protocol, there will be 1 PDT session followed by a consultation of control at 2 and 4 months after the end of treatment.
Conditions
- Dystrophic Epidermolysis Bullosa
Interventions
- PROCEDURE
-
Photodynamic therapy (PDT)
1 session of Photodynamic therapy (PDT) on epidermis dysplasia
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nice
lead OTHER
Principal Investigators
-
Christine CHIAVERINI, MD · Nice University Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-12-31
- Primary Completion
- 2014-06-30
- Completion
- 2015-06-30
Countries
- France
Study Locations
More Related Trials
-
Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
NCT06177353 ·Status: RECRUITING
-
Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
NCT04217538 ·Status: COMPLETED
-
Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa
NCT01768026 ·Status: WITHDRAWN
-
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT01019148 ·Status: RECRUITING
-
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
NCT04213261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT00904163 ·Status: COMPLETED
-
Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts
NCT04186650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NCT02810951 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
NCT02090283 ·Status: TERMINATED ·Phase: PHASE2
-
Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa
NCT04727268 ·Status: UNKNOWN
-
Computational Drug Repurposing for All EBS Cases
NCT03269474 ·Status: RECRUITING
-
Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa
NCT07230223 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)
NCT05248503 ·Status: COMPLETED
-
The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
NCT04214002 ·Status: WITHDRAWN
-
Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa
NCT01908088 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita
NCT00004359 ·Status: COMPLETED ·Phase: PHASE2
-
Short Term Observational Study in DEB Patients
NCT02178969 ·Status: COMPLETED
-
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
NCT06007235 ·Status: RECRUITING ·Phase: NA
-
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
NCT06917690 ·Status: RECRUITING ·Phase: PHASE3
-
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
NCT05143190 ·Status: COMPLETED ·Phase: PHASE2
-
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
NCT01263379 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)
NCT04757727 ·Status: COMPLETED
-
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
NCT04285294 ·Status: UNKNOWN
-
Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa
NCT05651607 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
NCT01340235 ·Status: UNKNOWN ·Phase: PHASE3